Your browser is out of date

With an updated browser, you will have a better Medtronic website experience.

×

Skip to main content

IN.PACT™ 018 Paclitaxel-coated PTA Balloon Catheter

Low profile. High performance.

IN.PACT™ 018 DCB combines a low-profile design and demonstrated technology to deliver lasting results to your patients with femoropopliteal disease.

Electric blue illustration showing lesion interfering with blood flow in a vessel on transparent background

Engineered to cross tight lesions and provide enhanced deliverability*1

Decorative element

5 Fr compatible
(4–6 mm diameter)

Electric blue illustration of a drug-coated balloon and catheter on a transparent background

130 and 200 cm catheter lengths provide the option of transradial† or femoral access

The same drug formulation as IN.PACT(TM) Admiral(TM), the DCB physicians widely choose.

Electric blue illustration of a drug-coated balloon

Uses the same proven formulation as IN.PACT™ Admiral™, the DCB physicians choose the most

   

Features

IN.PACT 018 DCB and catheter with circular numbers 1–4 as callouts

  

  1. Platinum-iridium marker bands
  2. Coaxial shaft
  3. FreePac™ coating
  4. 130 and 200 cm catheter lengths

Peel-away balloon protector

The IN.PACT™ 018 DCB features a peel-away balloon protector that helps preserve the integrity of the drug coating.

Learn more about IN.PACT (opens new window)
Illustration of peel away balloon protector feature on IN.PACT 018 DCB

Enhanced platform, trusted data

*Compared to standard PTA Balloon*

Medtronic IN.PACT 018 and IN.PACT Admiral drug-coated balloons allow you to2:

  • Choose your preferred treatment algorithm
  • Reduce guidewire exchanges*
  • Deliver long-term clinical outcomes

With 75% of patients remaining reintervention-free at five years,1 IN.PACT™ Admiral has:

  • High patency benefit through three years1
  • Most publications for a DCB‡

The safety and effectiveness of the IN.PACT Admiral DCB (.035 in guidewire compatible), as established in the clinical studies that were performed primarily via femoral access, can be considered supportive for the IN.PACT 018 DCB. The IN.PACT 018 DCB has not been evaluated in a clinical study.

Building on demonstrated technology

The IN.PACT™ 018 DCB uses the same formulation as IN.PACT™ Admiral DCB, so clinicians can expand their treatment options without compromising on safety and effectiveness.

IN.PACT™ DCBs are coated with a combination of paclitaxel and an excipient, urea. The proprietary coating allows rapid and efficient delivery of drug to the vessel wall.

This product is not available for purchase by the general public. This medical device must be administered by a healthcare professional.

ALWAYS READ THE LABEL AND FOLLOW THE DIRECTIONS FOR USE.

Reach a Medtronic sales
representative

Connect with us (opens new window)
Learn more about In.PACT (opens new window)

The safety and effectiveness of the IN.PACT™ Admiral DCB (.035 in guidewire compatible), as established in the clinical studies that were performed primarily via femoral access, can be considered supportive for the IN.PACT™ 018 DCB. The IN.PACT™ 018 DCB has not been evaluated in a clinical study.

*

Data on file with Medtronic.

†

Complications associated with radial access may include but are not limited to: abrupt vessel closure, vessel spasm, perforation or rupture of the artery, dissection, pseudoaneurysm, hematoma, thrombosis, and stroke.

‡

Publications on file with Medtronic.

References

1

Laird JA, Schneider PA, Jaff MR, et al. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions. 5-year results from the IN.PACT SFA Trial. Circ Cardiovasc Interv. June 2019;12(6):e007702.

2

Tepe G. 5-year results from the IN.PACT Global Study Prespecified Cohorts: ISR, CTO and Long Lesions. Presented at VIVA 2021.